Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition

ALK tyrosine kinase inhibition has become a mainstay in the clinical management of ALK fusion positive NSCLC patients. Although ALK mutations can reliably predict the likelihood of response to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, they cannot reliably predict response duration or...

Ausführliche Beschreibung